Neos Therapeutics Company Profile (NASDAQ:NEOS)

Analyst Ratings

Consensus Ratings for Neos Therapeutics (NASDAQ:NEOS) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.33 (186.25% upside)

Analysts' Ratings History for Neos Therapeutics (NASDAQ:NEOS)
Show:
DateFirmActionRatingPrice TargetActions
7/19/2016BMO Capital MarketsReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016Royal Bank Of CanadaLower Price TargetOutperform$33.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$33.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Neos Therapeutics (NASDAQ:NEOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
9/1/2016        
5/16/2016Q1($0.87)($0.79)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2016Q4($0.66)($0.57)$1.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/3/2015Q215($4.31)($7.76)$1.70 million$1.48 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neos Therapeutics (NASDAQ:NEOS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Neos Therapeutics (NASDAQ:NEOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Neos Therapeutics (NASDAQ:NEOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/13/2016Juergen MartensInsiderBuy10,000$9.90$99,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Alan L HellerDirectorBuy10,000$7.61$76,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Thomas P McdonnellInsiderBuy3,000$7.56$22,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Gregory J RobitailleDirectorBuy7,442$7.55$56,187.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016Presidio Partners 2007, L.P.Major ShareholderSell20,367$9.98$203,262.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Presidio Partners 2007, L.P.Major ShareholderSell57,968$10.23$593,012.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Neos Therapeutics (NASDAQ:NEOS)
DateHeadline
07/22/16 05:17 PMChecking in on Stock Volatility for: Neos Therapeutics, Inc. (NASDAQ:NEOS) - Engelwood Daily
07/22/16 05:17 PMNeos Therapeutics, Inc. (NEOS) Current Analyst Ratings - Fiscal Standard
07/22/16 05:17 PMNeos Therapeutics Incorporated (NASDAQ:NEOS) Shorted Shares Increased 32.23% After Market Selling - Consumer Eagle
07/22/16 05:17 PMWhat's Ahead for Neos Therapeutics Inc After Today's Huge Decline? - Press Telegraph
07/20/16 08:23 AMToday Neos Therapeutics Inc Stock Rises - Consumer Eagle
07/19/16 08:55 AMNew Broker Ratings For Neos Therapeutics, Inc. (NEOS) - FTSE News
07/17/16 04:52 PMNeos Therapeutics Incorporated (NASDAQ:NEOS) Shorted Shares Decreased By 5.06% - Consumer Eagle
07/17/16 04:52 PMShares Moving Down on the Week: Neos Therapeutics, Inc. (NASDAQ:NEOS) - Engelwood Daily
07/15/16 10:12 AMEye on Stock Volatility for: Neos Therapeutics, Inc. (NASDAQ:NEOS) - Engelwood Daily
07/15/16 10:12 AMHow Many Neos Therapeutics Inc (NASDAQ:NEOS)'s Analysts Are Bearish? - Press Telegraph
07/13/16 08:21 AMNeos Therapeutics Incorporated (NASDAQ:NEOS) Sellers Covered 5.06% of Their Shorts - Consumer Eagle
07/13/16 08:21 AMWhat's Neos Therapeutics Inc Downside After Forming Bearish Double Bottom? - Consumer Eagle
07/08/16 08:19 AMAre Analysts Bullish Neos Therapeutics Inc (NASDAQ:NEOS) After Last Week? - Press Telegraph
07/06/16 10:01 AMBMO Capital Initiates Coverage on Neos Therapeutics Inc to Outperform - TheFounders Daily
07/04/16 04:46 PMNeos Therapeutics, Inc. (NEOS) Broker Price Targets For The Coming Week - Fiscal Standard
07/02/16 05:05 PMUpdate on Stock Volatility for: Neos Therapeutics, Inc. (NASDAQ:NEOS) - Engelwood Daily
07/02/16 05:05 PMRecently Issued Stock Ratings For Neos Therapeutics, Inc. (NEOS) - Fiscal Standard
06/29/16 05:17 PMWatching Stock Volatility for: Neos Therapeutics, Inc. (NASDAQ:NEOS) - Engelwood Daily
06/28/16 10:15 AMNeos Therapeutics Incorporated (NASDAQ:NEOS) Short Interest Decreased By 5.06% - Press Telegraph
06/28/16 10:15 AMNext Weeks Broker Price Targets For Neos Therapeutics, Inc. (NEOS) - Fiscal Standard
06/20/16 07:03 AMThis Weeks Broker Views For Neos Therapeutics, Inc. (NEOS) - Fiscal Standard
06/17/16 08:10 AMNEOS THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
06/16/16 03:07 PMNEOS THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/14/16 06:29 AMNeos Therapeutics CEO to Present at JMP Securities Life Sciences Conference on June 21, 2016 - [at noodls] - DALLAS and FORT WORTH, Texas, June 14, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) ...
06/02/16 05:46 PMForm 4 Neos Therapeutics, Inc. For: Jun 01 Filed by: Martens Juergen - Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute ...
05/31/16 04:16 PMNEOS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Fina -
05/31/16 03:23 PMNeos Therapeutics Appoints Juergen Martens as Chief Technology and Operations Officer - [at noodls] - DALLAS and FORT WORTH, Texas, May 31, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) ...
05/27/16 12:24 PMHC Stocks Analysis: Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS) - share market updates (press release) - HC Stocks Analysis: Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS)share market updates (press release)Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) ended Wednesday session in green amid volatile trading. The shares closed up +4.91 points or 26.63% at $23.35 with 21.35 million shares getting traded. Post opening the session at $22.15, the shares ...
05/25/16 12:04 PMNEOS THERAPEUTICS, INC. Financials -
05/23/16 12:45 PMNeos Therapeutics, Inc. (NEOS) Broker Price Targets For The Coming Week - Share Trading News - Neos Therapeutics, Inc. (NEOS) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Neos Therapeutics, Inc. (NEOS). The latest reports which are currently in issue on Sunday 22nd of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
05/18/16 12:51 PMNeos Therapeutics (NEOS) Launches Adzenys XR-ODT in the U.S. - StreetInsider.com - Neos Therapeutics (NEOS) Launches Adzenys XR-ODT in the U.S.StreetInsider.comNeos Therapeutics, Inc. (Nasdaq: NEOS) announced that Adzenys XR-ODT is in distribution channels and is now available to prescribe to patients with ADHD in the United States. Adzenys XR-ODT was approved by the U.S. Food and Drug Administration ...
05/18/16 12:51 PMNeos Therapeutics Announces U.S. Launch of Adzenys XR-ODT™ (Amphetamine Extended-Release Orally ... - GlobeNewswire (press release) - Philly.comNeos Therapeutics Announces U.S. Launch of Adzenys XR-ODT™ (Amphetamine Extended-Release Orally ...GlobeNewswire (press release)DALLAS and FORT WORTH, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of ...Neos Therapeutics Reports Narrower-than-Expected Q1 Loss as Revenue Surges — Shares Gain 2% (NASDAQ:NEOS)Sonoran Weekly ReviewNeos' ADHD drug hits the marketPhilly.comNeos Therapeutics Announces Closing of $60 Million Term Debt Financing and First Quarter 2016 Financial ResultsForexTV.comSeeking Alpha -Philadelphia Business Journalall 7 news articles »
05/17/16 12:56 PMBRIEF-Neos Therapeutics says Adzenys XR-ODT is available to prescribe to patients with ADHD in United States - Reuters - BRIEF-Neos Therapeutics says Adzenys XR-ODT is available to prescribe to patients with ADHD in United StatesReutersBRIEF-Neos Therapeutics says Adzenys XR-ODT is available to prescribe to patients with ADHD in United States. May 16 Neos Therapeutics Inc. * Adzenys xr-odt is in distribution channels and is now available to prescribe to patients with ADHD in United ...
05/17/16 12:56 PMNeos' ADHD drug hits the market - Philly.com - Philly.comNeos' ADHD drug hits the marketPhilly.comNeos Therapeutics Inc. said Monday that its first-of-a-kind treatment for attention deficit hyperactivity disorder is now available in pharmacies for physicians to prescribe. The small Texas company with a sales and marketing headquarters in Blue Bell ...Neos Therapeutics Announces U.S. Launch of Adzenys XR-ODT™ (Amphetamine Extended-Release Orally ...GlobeNewswire (press release)Neos Therapeutics Reports Narrower-than-Expected Q1 Loss as Revenue Surges — Shares Gain 2% (NASDAQ:NEOS)Sonoran Weekly ReviewNeos Therapeutics' (NEOS) CEO Vipin K. Garg on Q1 2016 Results - Earnings Call TranscriptSeeking AlphaPhiladelphia Business Journalall 7 news articles »
05/17/16 12:56 PMNeos Therapeutics CEO to Present at 2016 UBS Healthcare Conference on May 24, 2016 - Nasdaq - Neos Therapeutics CEO to Present at 2016 UBS Healthcare Conference on May 24, 2016NasdaqDALLAS and FORT WORTH, Texas, May 17, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of ...Neos Therapeutics Inc (NEOS) is Reiterated by RBC Capital Mkts to Outperform, Lowers Price Target to $ 29Market Digestall 2 news articles »
05/17/16 12:56 PMNeos announces U.S. launch of Adzenys XR-ODT for ADHD - Neos Therapeutics, Inc., a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Adzenys XR-ODT™ is in ...
05/17/16 12:56 PMNeos Therapeutics : ' ADHD drug hits the market - May 16--Neos Therapeutics Inc. said Monday that its first-of-a-kind treatment for attention deficit hyperactivity disorder is now available in pharmacies for physicians to prescribe. The small Texas company with a sales and marketing headquarters in Blue ...
05/17/16 07:42 AMNeos Therapeutics CEO to Present at 2016 UBS Healthcare Conference on May 24, 2016 - [at noodls] - DALLAS and FORT WORTH, Texas, May 17, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) ...
05/16/16 02:23 PMEdited Transcript of NEOS earnings conference call or presentation 16-May-16 12:30pm GMT -
05/16/16 12:39 PMBRIEF-Neos Therapeutics Q1 revenue $2.6 million - Reuters - BRIEF-Neos Therapeutics Q1 revenue $2.6 millionReutersMay 16 Neos Therapeutics Inc : * Neos Therapeutics Inc qtrly net loss per share attributable to common stock, basic and diluted $0.79. * Q1 earnings per share view $-0.86 -- Thomson Reuters I/B/E/S. * Neos Therapeutics announces closing of $60 million ...
05/16/16 12:39 PMNeos Therapeutics reports 1Q loss - Money Morning - Neos Therapeutics reports 1Q lossMoney MorningGRAND PRAIRIE, Texas (AP) _ Neos Therapeutics Inc. (NEOS) on Monday reported a loss of $12.6 million in its first quarter. On a per-share basis, the Grand Prairie, Texas-based company said it had a loss of 79 cents. The pharmaceutical company posted ...and more »
05/16/16 12:39 PMNeos Therapeutics Announces Closing of $60 Million Term Debt Financing and First Quarter 2016 Financial Results - GlobeNewswire (press release) - Neos Therapeutics Announces Closing of $60 Million Term Debt Financing and First Quarter 2016 Financial ResultsGlobeNewswire (press release)DALLAS and FORT WORTH, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of ...Neos Therapeutics Reports Narrower-than-Expected Q1 Loss as Revenue Surges — Shares Gain 2% (NASDAQ:NEOS)Sonoran Weekly ReviewNeos Therapeutics Announces U.S. Launch of Adzenys XR-ODT™ (Amphetamine Extended-Release Orally ...Virtual-Strategy MagazineNeos Therapeutics' (NEOS) CEO Vipin K. Garg on Q1 2016 Results - Earnings Call TranscriptSeeking Alphaall 5 news articles »
05/16/16 12:39 PMNeos Therapeutics Inc Earnings Call (Q1 2016) - Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. Its product candidates ...
05/16/16 07:30 AMNeos Therapeutics Inc Earnings Call scheduled for 8:30 am ET today -
05/16/16 06:07 AMQ1 2016 Neos Therapeutics Inc Earnings Release - Before Market Open -
05/16/16 05:43 AMNEOS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Fin -
05/16/16 05:35 AMNeos Therapeutics reports 1Q loss -
05/16/16 05:22 AMNeos Therapeutics Announces U.S. Launch of Adzenys XR-ODT™ (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients Six Years and Older - [at noodls] - DALLAS and FORT WORTH, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates ...
05/16/16 05:22 AMNeos Therapeutics Announces Closing of $60 Million Term Debt Financing and First Quarter 2016 Financial Results - [at noodls] - DALLAS and FORT WORTH, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) ...
05/16/16 05:03 AM6:03 am Neos Therapeutics announces that Adzenys XR-ODT is in distribution channels and is now available to prescribe to patients with ADHD in the US -

Social

About Neos Therapeutics

Neos Therapeutics logoNeos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NEOS
  • CUSIP:
Key Metrics:
  • Previous Close: $8.85
  • 50 Day Moving Average: $9.48
  • 200 Day Moving Average: $9.90
  • P/E Ratio: N/A
  • P/E Growth: -0.02
  • Market Cap: $142.00M
  • Current Year EPS Consensus Estimate: $-4.07 EPS
  • Next Year EPS Consensus Estimate: $-2.32 EPS
Additional Links:
Neos Therapeutics (NASDAQ:NEOS) Chart for Monday, July, 25, 2016